ONCOLOGY INSTITUTE 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: Starling Oncology delivered a strong Q2 2026 with revenue of $161.3 million, up 34.6% year over year, driven primarily by specialty pharmacy growth (+57.6% to $98.6 million). Gross profit rose to $27.2 million and gross margin improved to 16.8% from 14.6%. Adjusted EBITDA was positive at $0.2 million, marking the company’s second profitable quarter as a public company. Operating leverage improved, with SG&A down to 18.6% of revenue from 22.5% a year ago. Free cash flow was $12.5 million in the quarter and year-to-date was positive $9.5 million.

Company Outlook & Strategy: Management raised full-year 2026 guidance to revenue of $650 million–$670 million and gross profit of $105 million–$110 million, while tightening adjusted EBITDA guidance to $2 million–$7 million and maintaining free cash flow guidance of $5 million–$15 million. The company expects 2026 to be its first full year of positive adjusted EBITDA as a public company. Strategic priorities include scaling delegated capitated contracts, expanding outside Florida, and investing ahead of expected 100% growth in capitated revenue next year. The company also completed a refinancing with OrbiMed that extended maturities to 2031 and improved liquidity without equity dilution.

Key Industry Trends: The call highlighted continued momentum in value-based oncology and delegated capitation, with expansion into Nevada and Oregon representing the company’s first such model outside Florida. Management emphasized growing demand for coordinated, tech-enabled cancer care, increased use of pharmacy and ancillary services, and data-driven care pathway management.

Operational Highlights: Starling will rebrand as Starling Oncology to better reflect its national, value-based oncology platform. The company is launching Starling Nexus, a new provider portal, in mid-August to streamline treatment orders and prior authorizations, improve pathway adherence, and support ancillary services like Part D pharmacy and decentralized clinical trials. It also negotiated additional vendor fee reductions, generating over $1 million of annualized OpEx savings. New contracts are expected to add about 80,000 lives and $50 million of annualized capitated revenue, plus an additional 230,000 capitated lives and about $6 million in annualized capitation from California exclusivity.

Challenges & Risks: Near-term profitability is being tempered by onboarding costs, clinical staffing ahead of launches, and MLR pressure as new members ramp. Management noted the Q3 delegated contract launch was pushed back by two months to October 1, and Q3 adjusted EBITDA is expected to be only modestly positive. MLR was 85.5% in Q2 and is expected to remain in the 80%–90% range over the next 12 months as the company absorbs new lives.

Key Analyst Questions & Responses: The main Q&A topic was the Nevada and Oregon expansion. Management confirmed there is one contract in each state and framed them as important wins that expand the delegated capitation model beyond Florida. While the transcript cuts off before a full numeric response, management indicated these contracts are meaningful additions to membership and revenue, consistent with the earlier disclosure of 80,000 incremental lives and about $50 million in annualized capitated revenue from the three new contracts.